Sanofi offers to acquire Kiadis

Adds proprietary next generation natural killer (K-NK) cell platform and pipeline of cell-based cancer immune-therapeutics and infectious disease therapies

02-Nov-2020 - Sanofi and Kiadis, a clinical-stage biopharmaceutical company developing innovative ‘off the shelf’ natural killer (NK) cell based medicines for the treatment of life-threatening diseases, entered into a definitive agreement under which Sanofi will make a public offer (subject to satisfaction of ...

Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM)

ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor

02-Dec-2009 - Kiadis Pharma announced that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched ...

Kiadis Pharma receives two orphan drug designations for Reviroc from the FDA

10-Dec-2008 - Kiadis Pharma announces that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc™ Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of ...

Kiadis Pharma announces positive clinical results for ATIR in mismatched bone marrow transplantations

09-Dec-2008 - Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR™ phase I/II clinical trial. ATIR™, a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a ...

EMEA grants Kiadis Pharma lead product ATIR orphan drug designation

24-Sep-2008 - Kiadis Pharma announced that its lead product ATIR™ has been granted orphan drug designation (ODD) by the European Medicines Agency (EMEA) for the prevention of acute Graft versus Host Disease (GvHD) following an allogeneic bone marrow transplantation. “Following the orphan drug designation ...

Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany

02-Jun-2008 - Kiadis Pharma announced the clinical development collaboration for its lead product ATIR(TM) with Dr. Stephan Mielke and Professor Dr. Hermann Einsele from the Allogeneic Stem Cell Transplant Center, Division of Hematology and Oncology, Department of Internal Medicine II at the Julius-Maximilians ...

Kiadis Pharma receives Orphan Drug Designation for Rhitol(TM) from the FDA

17-Apr-2008 - Kiadis Pharma announced that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol(TM) Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become ...

ATIR classified as "cell based" medicinal product by the EMEA

18-Dec-2007 - Kiadis Pharma announced that its lead product ATIR has received approval for regulatory classification as a "cell based" medicinal product by the Innovation Task Force (ITF), a division of the European Medicines Agency (EMEA). Based upon this regulatory classification ATIR is eligible for EMEA ...

Kiadis Pharma Presents ATIR and Rhitol Data and NIH Presentation on ATIR

27-Nov-2007 - Kiadis Pharma announced that there will be three presentations on its products ATIR and Rhitol in poster sessions at the 2007 Annual Meeting of the American Society of Hematology (ASH) December 8-11 in Atlanta, Georgia, USA. Data will be presented from the companies ongoing clinical study on ATIR ...

Kiadis and Celmed Merge to Create New Force in Oncology

30-Nov-2006 - Kiadis B.V. and Celmed BioSciences announced their plans to merge both oncology-focused companies. The combined company will be named Kiadis Pharma B.V. and headquartered in the Netherlands with facilities in the Netherlands and Canada. According to the company, Kiadis Pharma is fully dedicated ...